Quantitative Detection of the M204V Hepatitis B Virus Minor Variants by Amplification Refractory Mutation System Real-Time PCR Combined with Molecular Beacon Technology
- 1 August 2009
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 47 (8) , 2544-2550
Abstract
Mutations in the highly conserved tyrosine-methionine-aspartate-aspartate (YMDD) motif are frequently associated with resistance to antivirals and represent a major concern in the treatment of hepatitis B virus (HBV) infection. Conventional methods fail to detect minority populations of drug-resistant viral quasispecies if they represent less than 25% of the total sample virus population. The amplification refractory mutation system real-time PCR (ARMS RT-PCR) was combined with molecular beacon technology using the LightCycler system. The samples from HBV patients selected for assay evaluation included (i) 57 samples from treatment-naive patients for biological discriminatory ability (cutoff) estimation, (ii) 12 samples from patients with treatment failure that were M204V positive by sequencing, and (iii) 13 samples from patients with treatment failure that were negative for mutation at codon 204 by sequencing. The discriminatory ability of the assay was 0.25% when tested with laboratory-synthesized DNA target sequences. The median mutant-to-wild-type ratio for samples from naive patients tested positive for the wild type and for mutant variants was 0.01% (5th and 95th percentiles = 0.0001 and 0.04%, respectively). A value of 0.04% was selected as the biological cutoff of the assay of clinical samples. In all samples M204V positive by sequencing (12/12), the mutant variant was detected as the predominant population (range, 82.76 to 99.43%). Interestingly, in 5 (38%) of 13 samples negative by sequencing, the M204V variant was detected at a ratio above the biological cutoff (0.05 to 28%). The assay represents an efficient technique for the early detection and quantification of M204V variants before mutant strains emerge to dominate the population.Keywords
This publication has 35 references indexed in Scilit:
- Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCRJournal of Hepatology, 2004
- Evaluation of the INNO-LiPA HBV Genotyping Assay for Determination of Hepatitis B Virus GenotypeJournal of Clinical Microbiology, 2003
- The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In VitroJournal of Virology, 2003
- Rapid and Sensitive Assays for Determination of Hepatitis B Virus (HBV) Genotypes and Detection of HBV Precore and Core Promoter VariantsJournal of Clinical Microbiology, 2003
- Fatal Submassive Hepatic Necrosis Associated with Tyrosine‐Methionine‐Aspartate‐Aspartate–Motif Mutation of Hepatitis B Virus after Long‐Term Lamivudine TherapyClinical Infectious Diseases, 2001
- Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapyHepatology, 1999
- Ymdd Motif in Hepatitis B Virus Dna Polymerase Influences on Replication and Lamivudine Resistance: A Study By In Vitro Full–Length Viral Dna TransfectionHepatology, 1999
- Identification and characterization of mutations in hepatitis B virus resistant to lamivudineHepatology, 1998
- Taking DNA probes into a protein worldNature Biotechnology, 1996
- CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choiceNucleic Acids Research, 1994